Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 10 Carcinoma, Non-Small-Cell Lung 10 Carcinoma, Hepatocellular 8 Lung Neoplasms 6 Colorectal Neoplasms 6 Neoplasms 5 Prostatic Neoplasms 4 Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Small Cell Lung Cancer Extensive Stage 2 Sarcoma, Alveolar Soft Part 2 Sarcoma 2 Ovarian Neoplasms 2 Mesothelioma, Malignant 2 Melanoma 2 Liver Neoplasms 2 Extensive Stage Lung Small Cell Carcinoma 2 Carcinoma, Renal Cell 2 Carcinoma 2 Wilms Tumor 1 Vulvar Neoplasms 1 Vaccinia 1 Sarcoma, Clear Cell 1 Rhabdomyosarcoma 1 Papillary renal cell carcinoma, sporadic 1 PIK3CA-Mutated Cancers 1 Osteosarcoma 1

Interventions

X-Rays 5 Phantoms, Imaging 5 Magnetic Resonance Spectroscopy 5 Nuclear Medicine Department, Hospital 4 Cyclophosphamide 4 fludarabine 3 Specimen Handling 3 Doxorubicin 3 Biopsy 3 ulixertinib 2 tipifarnib 2 selpercatinib 2 olaparib 2 larotrectinib 2 ivosidenib 2 ensartinib 2 cabozantinib 2 Methotrexate 2 Mesna 2 Ifosfamide 2 Gemcitabine 2 Eflornithine 2 Cisplatin 2 tazemetostat 1 talazoparib 1 selinexor 1 pazopanib 1 palbociclib 1 mifamurtide 1 merphos 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Osteosarcoma × atezolizumab × 30 days × Clear all

NCT06492954 2026-06-02

AflacST2301

Emory University

Phase 1 Recruiting

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡